Alpha memo: selenium cancer prevention vitamin endpoint split

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Provide an actual bounded signal that the two receipts jointly establish (e.g., concordant null on prostate cancer incidence with a divergent vitamin E harm signal in Receipt 1) rather than asserting an 'endpoint split' that the bundle does not demonstrate.
2. Replace verbatim receipt quotes in abstract and body with memo-authored synthesis grounded in the cited findings.
3. Differentiate the two receipts by what each uniquely contributes (Receipt 1: 7-year results + vitamin E harm signal; Receipt 2: mechanistic/biologic interpretation) and state a concrete, falsifiable alpha tied to that distinction.
4. Add a real gaps section identifying actionable next-step uncertainties (e.g., baseline-selenium-status stratified trials, selenoprotein genotype interactions, vitamin E dose-response reconciliation).
5. Rename the title to match what the receipts actually show, e.g., 'SELECT concordant null plus vitamin E harm signal' rather than 'endpoint split.'

Major issues

• The memo reports no novel research signal: both receipts describe the same SELECT trial null result, so the 'endpoint split' framing is not actually demonstrated by the evidence bundle—it is asserted but not shown to be a split rather than a uniform null.
• The abstract, 'one-sentence alpha,' and 'why this is surprising' sections are largely verbatim recitations of receipt excerpts rather than an integrated synthesis, indicating the memo was assembled by stitching receipt text rather than analyzing it.
• No genuine novelty: bundling two papers about the same SELECT trial and labeling it a 'population/endpoint split' overstates what two concordant null findings can support.

Minor issues

• Title promises a 'vitamin endpoint split' but the receipts do not separately demonstrate distinct endpoints—one receipt reports the 7-year prostate cancer incidence null plus the vitamin E 17% increased risk signal, the other reports the prostate cancer null only; the memo never clearly distinguishes or contrasts these endpoint families.
• Gaps section is absent; the brief 'caveats/falsifiers' list contains procedural falsifiers rather than substantive next-step research gaps.
• Source descriptions quote receipt language verbatim rather than summarizing, blurring the boundary between memo prose and source excerpts.

Reviewer note

This alpha memo bundles two papers that report on the same SELECT trial and largely concordant null findings on prostate cancer incidence. The proposed 'population/endpoint split' signal is not actually demonstrated by the evidence: Receipt 1 reports the 7-year prostate cancer null plus a vitamin E 17% increased risk signal, while Receipt 2 reports the prostate cancer null with a mechanistic/biology interpretation. The memo never clearly distinguishes two separable endpoint families or shows that the population/endpoint characteristics diverge across the two receipts. Instead, the abstract and body sections recycle verbatim receipt text, producing a stitched rather than synthesized artifact. The title's promise of a 'vitamin endpoint split' overstates what two concordant nulls can support. A genuine alpha memo here would be either (a) the SELECT concordant null plus the unexpected vitamin E harm signal as a bounded secondary finding, or (b) the mechanistic explanation (formulation, baseline selenium status) as the bridge between null trial results and prior positive preclinical/observational evidence. As submitted, the memo lacks a differentiated signal, substitutes quotation for synthesis, and overclaims the contrast between the two receipts. Reject; a rewrite could salvage the receipt pair into a competent bounded memo.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis